文献速递药物不良反应与药物警戒治疗药物监测与药物基因组学

CFTR调节剂相关肝毒性病例系列及药物遗传学多态性可能相关性

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients.
PubMed 文献 · Br J Clin Pharmacol · 2026-06-25

该病例系列评估了6例使用CFTR调节剂后出现肝毒性的囊性纤维化患者,采用RECAM评分判定,并检测CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1等基因多态性。结果显示CYP3A4*22等位基因频率高于欧洲人群,该变异降低CYP3A活性,可能减少CFTR调节剂清除并增加肝毒性风险,但需进一步研究证实。

要点

  • CYP3A4*22等位基因频率在6例肝毒性患者中高于欧洲人群。
  • 该变异降低CYP3A活性,可能减少CFTR调节剂清除。
  • 肝毒性机制可能涉及多个药物代谢与解毒基因多态性。

核心结论

  • CYP3A4*22等位基因频率在CFTR调节剂相关肝毒性患者中高于欧洲人群,可能通过降低CYP3A活性减少药物清除并增加肝毒性风险。
  • 其他遗传因素也可能参与肝毒性发生,需进一步研究确认。

研究设计与样本

  • 描述性病例系列,纳入6例使用CFTR调节剂后出现肝毒性的囊性纤维化患者。
  • 采用RECAM评分评估肝毒性,并检测CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1基因多态性。

主要发现

  • 6例患者均在使用CFTR调节剂期间出现肝毒性。
  • CYP3A4*22(rs35599367)等位基因频率高于欧洲人群。
  • 该变异降低CYP3A活性,可能减少CFTR调节剂清除并增加肝毒性风险。
  • 其他遗传因素可能也参与肝毒性。

关键数值与推荐

  • 肝毒性评估采用RECAM评分。
  • 检测的基因多态性包括CYP3A4、CYP3A5、ABCB1、SLCO1B1、GSTP1、GSTM1、GSTT1。
  • CYP3A4*22等位基因频率高于欧洲人群。

临床怎么用

  • 对使用CFTR调节剂的患者,可关注CYP3A4*22等位基因状态以评估肝毒性风险。
  • 肝毒性发生时应考虑药物遗传学因素,必要时进行基因检测。

局限性

  • 样本量仅6例,结果需进一步研究证实。
  • 其他遗传因素的作用尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Laffitte Redondo C, Bourdin V, Ait Tayeb AEK, et al. A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients. Br J Clin Pharmacol. 2026. PMID: 42346180. doi:10.1002/bcp.70660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。